Amarin Corporation (Nasdaq:AMRN), has announced that data from each of its two pivotal Phase 3 studies, the ANCHOR trial and the MARINE trial, will be presented at the American Heart Association's Scientific Sessions 2011 in Orlando, Fla.
The presentation of the ANCHOR trial results will be the first presentation of data from this trial at a scientific session. The presentation of MARINE trial results will include data that has not been previously presented.
The ANCHOR trial results will be presented in an abstract by Christie M. Ballantyne, M.D., Methodist DeBakey Heart and Vascular Center, Houston, and principal investigator of the ANCHOR trial. This abstract is scheduled to be presented in an oral session on Wednesday, November 16, 2011 at 10:00 am ET. The presentation will be part of a scientific session titled "Novel Lipid Modifying Therapies and Other Atheropreventive Treatments."
The additional MARINE data will be presented in an abstract titled "Effects of AMR101, a Pure Ethyl Eicosapentaenoic Acid Omega-3 Fatty Acid, on Lipoprotein Particle Concentration and Size in Patients with Very High Triglycerides (the MARINE Study) by Harold Bays, M.D., Medical Director, Louisville Metabolic and Atherosclerosis Research Center, and principal investigator of the study. This abstract is scheduled to be orally presented on Tuesday, November 15, 2011 at 4:45 pm ET. The presentation will be part of a scientific session titled "New Frontiers in Lipid Management."
Following the presentation of ANCHOR results at the above forum in November, Amarin, together with clinical investigators from the ANCHOR study, plans to publish additional data from the ANCHOR trial. Results of the MARINE study will be published in the September issue of The American Journal of Cardiology. A separate oral presentation of MARINE trial results is also scheduled to be presented on August 29, 2011 at 11:45 am CEST at the annual meeting of the European Society of Cardiology in Paris.
In addition, a look at the FDA Trade Catalyst Calendar shows a couple of additional upcoming regulatory catalysts for AMRN in the near term.
Amarin's cardiovascular programs capitalize on its expertise in the field of lipid science and the known therapeutic benefits of essential fatty acids in cardiovascular disease. The company's cardiovascular pipeline includes AMR101 entering Phase 3 for hypertriglyceridemia and a preclinical program of new lipid compounds.Amarin's pipeline also includes a range of candidates in development to treat central nervous system (CNS) disorders, all of which are available for partnering. The AMR101 prevents cardiovascular events, treats high triglycerides and treats high triglycerides in patients with mixed Dyslipidemia.Amarin has collaborations with Medpace, Inc., Scarista Limited, Elan Corp. Plc, MultiCell Technologies Inc, Valeant Pharmaceuticals International etc.
"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'. Add this page to your favorite Social Bookmarking websites